Werner Freier

1.6k total citations
28 papers, 760 citations indexed

About

Werner Freier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Werner Freier has authored 28 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Werner Freier's work include Colorectal Cancer Treatments and Studies (15 papers), Cancer Treatment and Pharmacology (14 papers) and Renal cell carcinoma treatment (5 papers). Werner Freier is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Cancer Treatment and Pharmacology (14 papers) and Renal cell carcinoma treatment (5 papers). Werner Freier collaborates with scholars based in Germany, United States and Netherlands. Werner Freier's co-authors include Hans‐Joachim Schmoll, Ullrich Graeven, Axel Hinke, Wolff Schmiegel, Rainer Porschen, Thomas Seufferlein, Hendrik‐Tobias Arkenau, Axel Grothey, Albrecht Kretzschmar and Richard Greil and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Werner Freier

26 papers receiving 735 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Werner Freier Germany	15	513	360	186	143	129	28	760
Christopher Hagenstad United States	8	687 1.3×	297 0.8×	168 0.9×	198 1.4×	89 0.7×	14	847
Seta Shahin United States	8	812 1.6×	319 0.9×	120 0.6×	186 1.3×	127 1.0×	13	948
Federico Nasroulah United States	11	824 1.6×	395 1.1×	206 1.1×	190 1.3×	150 1.2×	29	993
Roger Sidhu United States	13	715 1.4×	388 1.1×	139 0.7×	152 1.1×	165 1.3×	29	904
Vicente Alonso-Orduña Spain	7	832 1.6×	402 1.1×	143 0.8×	261 1.8×	135 1.0×	23	1.0k
R Castan France	4	829 1.6×	392 1.1×	200 1.1×	288 2.0×	140 1.1×	6	1.0k
Christian Lerchenmüller Germany	16	582 1.1×	417 1.2×	182 1.0×	128 0.9×	164 1.3×	49	890
Scot Dowden Canada	14	624 1.2×	285 0.8×	81 0.4×	124 0.9×	177 1.4×	24	826
Audrey Hamilton United States	4	783 1.5×	418 1.2×	138 0.7×	100 0.7×	97 0.8×	17	922
A. Misino Italy	11	755 1.5×	368 1.0×	134 0.7×	221 1.5×	134 1.0×	25	983

Countries citing papers authored by Werner Freier

Since Specialization

Citations

This map shows the geographic impact of Werner Freier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Werner Freier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Werner Freier more than expected).

Fields of papers citing papers by Werner Freier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Werner Freier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Werner Freier. The network helps show where Werner Freier may publish in the future.

Co-authorship network of co-authors of Werner Freier

This figure shows the co-authorship network connecting the top 25 collaborators of Werner Freier. A scholar is included among the top collaborators of Werner Freier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Werner Freier. Werner Freier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riecke, Armin, Eugen Tausch, Deyan Y. Yosifov, et al.. (2023). Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial. Blood. 142(Supplement 1). 199–199.

Honecker, Friedemann, Gerd Kallischnigg, Werner Freier, et al.. (2021). Patient assessment and feasibility of treatment in older patients with cancer: results from the IN-GHO® Registry. Journal of Cancer Research and Clinical Oncology. 147(11). 3183–3194.

Jordan, Karin, Tim Luetkens, C. Gog, et al.. (2016). Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108. European Journal of Cancer. 63. 127–134. 20 indexed citations

Eichelberg, Christian, Walter L. Vervenne, Maria De Santis, et al.. (2015). SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European Urology. 68(5). 837–847. 111 indexed citations

Marschner, Norbert, et al.. (2015). Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study. Clinical Epidemiology. 7. 295–295. 19 indexed citations

Eichelberg, Christian, Walter L. Vervenne, Maria De Santis, et al.. (2014). Updated Os Analysis, Multivariate and Qtwist Analysis of a Randomized Sequential Open-Label Study (Switch) to Evaluate Efficacy and Safety of Sorafenib (So) / Sunitinib (Su) Versus Su/So in the Treatment of Metastatic Renal Cell Cancer (Mrcc). Annals of Oncology. 25. iv290–iv290. 4 indexed citations

Michel, Maurice Stephan, Walter L. Vervenne, Maria De Santis, et al.. (2014). SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology. 32(4_suppl). 393–393. 32 indexed citations

Goebell, Peter J., Walter L. Vervenne, Maria De Santis, et al.. (2014). Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology. 32(15_suppl). 4567–4567. 9 indexed citations

Niederle, N., Leopold Balleisen, W. Heit, et al.. (2013). Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Annals of Hematology. 92(5). 653–660. 30 indexed citations

10.

Schmiegel, Wolff, A. Reinacher-Schick, Dirk Arnold, et al.. (2013). Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Annals of Oncology. 24(6). 1580–1587. 53 indexed citations

11.

Michel, Maurice Stephan, Walter L. Vervenne, Peter J. Goebell, et al.. (2012). Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results.. Journal of Clinical Oncology. 30(15_suppl). 4539–4539. 8 indexed citations

12.

Stemmler, Hans‐Joachim, Werner Freier, G. Gitsch, et al.. (2011). Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer. 104(7). 1071–1078. 29 indexed citations

13.

Schmid, Peter, Dagmar Kühnhardt, Philipp Kiewe, et al.. (2008). A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Annals of Oncology. 19(5). 871–876. 40 indexed citations

14.

Arkenau, Hendrik‐Tobias, Ullrich Graeven, S. Kubicka, et al.. (2008). Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 7(1). 60–64. 27 indexed citations

15.

Reinacher-Schick, A., Stefan Kubicka, Werner Freier, et al.. (2008). Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). Journal of Clinical Oncology. 26(15_suppl). 4030–4030. 36 indexed citations

16.

Freier, Werner, et al.. (2007). Palliativmedizinische Erfahrungen deutscher Hausärzte. DMW - Deutsche Medizinische Wochenschrift. 132(49). 2620–2623. 15 indexed citations

17.

Porschen, Rainer, Hendrik‐Tobias Arkenau, S. Kubicka, et al.. (2007). Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. Journal of Clinical Oncology. 25(27). 4217–4223. 216 indexed citations

18.

Reinacher-Schick, A., Michael Geißler, Ullrich Graeven, et al.. (2007). Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) vs. capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI study group. Zeitschrift für Gastroenterologie. 45(8). 2 indexed citations

19.

Possinger, K., Walter Schippinger, Philipp Kiewe, et al.. (2005). Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Journal of Clinical Oncology. 23(16_suppl). 755–755. 3 indexed citations

20.

Rosenthal, H., Werner Freier, & M. Galanski. (1991). [Complications of osteosynthesis in the x-ray picture].. PubMed. 31(4). 186–91. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact